Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	10.66B -2.6%
Revenue (ttm)	1.94B +19.6%
Net Income	327.00M -19.1%
EPS	1.04 -20.9%
Shares Out	316.05M
PE Ratio	32.42
Forward PE	14.82
Dividend	0.64 (1.98%)
Ex-Dividend Date	n/a

Volume	5,344,733
Average Volume	3,651,598
Open	32.48
Previous Close	32.49
Day's Range	32.48 - 34.30
52-Week Range	29.86 - 50.86
Beta	0.33
RSI	45.75
Earnings Date	Apr 30, 2026

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 2,247
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2025, SHA:688076's revenue was 1.94 billion, an increase of 19.57% compared to the previous year's 1.62 billion. Earnings were 327.00 million, a decrease of -19.14%.